NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Levi &Â Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. ...

LOS ANGELES--(BUSINESS WIRE)---- $CYTK--CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm. ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Cytokinetics (CYTK) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- What’s H ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Cytokinetics, Incorporated ("Cytokinetics†or the "Company†) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the "Class Period†). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CYTOKINETICS, INCORPORATED (CYTK), CONTACT THE LAW. ...

LOS ANGELES, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Inc., (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of investors that bought securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetic investors have until November 17, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss the ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 18, 2025 ...

We recently published 10 Big Names Investors Are Dumping. Cytokinetics, Inc. (NASDAQ:CYTK) is one of the worst performers on Wednesday. Shares of Cytokinetics dropped by 4.42 percent on Wednesday to end at $47.56 apiece after upsizing its senior convertible notes issuance to $650 million. In a statement, Cytokinetics, Inc. (NASDAQ:CYTK) said it aimed to raise $650 million from the offer, an increase from the $550 million targeted initially. The notes carry a yield rate of 1.75 percent until 2031 and will ...

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants made materially false and mi ...

诉讼核心指控 - 股东对Cytokinetics公司提起集体诉讼，指控公司未能披露与未提交风险评估和缓解策略相关的重大风险，该风险可能延迟监管审批流程[1] - 诉讼指控公司曾表示基于2025年9月26日的处方药用户费用法案日期，预计其新药aficamten将在2025年下半年获得美国食品药品监督管理局批准[1] 诉讼相关方及时间 - 诉讼涉及在2023年12月27日至2025年5月6日期间购买公司股票并遭受重大损失的股东[2] - 法院指定的首席原告申请截止日期为2025年11月17日[3] - 代理律所Holzer & Holzer, LLC自2000年成立以来已为股东追回数亿美元损失[3]

公司近期动态 - Cytokinetics公司宣布将在2025年9月26日至29日于明尼阿波利斯举行的美国心力衰竭协会（HFSA）2025年度科学会议上进行三项研究成果展示，包括两项最新突破性临床研究和一项海报展示[1] - 两项最新突破性临床研究均安排在2025年9月28日进行，主题为"最新突破性临床研究1：装置与心肌病"，地点在主礼堂[2] 研究数据发布详情 - FOREST-HCM研究的96周长期数据分析将展示Aficamten在非梗阻性肥厚型心肌病患者中的安全性与有效性，由俄勒冈健康与科学大学肥厚型心肌病中心主任Ahmad Masri博士陈述，展示时间为中部时间上午9:50[2] - MAPLE-HCM的预设分析将展示Aficamten与美托洛尔对梗阻性肥厚型心肌病患者运动能力的不同影响，由哈佛医学院医学教授Gregory Lewis博士陈述，展示时间为中部时间上午9:58[2] - 一项关于非梗阻性肥厚型心肌病患者社会人口学特征与医疗成本关联的海报展示将由宾夕法尼亚大学医院心血管医学助理教授Nosheen Reza博士进行，时间为中部时间上午7:45至8:45[3] 核心产品Aficamten研发进展 - Aficamten是一种研究性的选择性小分子心肌肌球蛋白抑制剂，旨在通过减少每个心动周期中活跃的肌动蛋白-肌球蛋白横桥数量来抑制与HCM相关的心肌过度收缩[3] - Aficamten研发项目评估其通过峰值摄氧量改善HCM患者运动能力和缓解症状的潜力，已在针对症状性梗阻性HCM患者的SEQUOIA-HCM关键三期临床试验中获得阳性结果[4] - Aficamten已获得美国FDA授予的治疗症状性HCM突破性疗法认定，以及中国国家药品监督管理局授予的治疗症状性梗阻性HCM突破性疗法认定[4] - Aficamten目前正在多项三期临床试验中进行评估，包括针对非梗阻性HCM患者的ACACIA-HCM、针对儿科oHCM患者的CEDAR-HCM以及针对HCM患者的开放标签扩展临床研究FOREST-HCM[5] 监管审批状态 - Aficamten作为一种研究性药物，尚未获得任何监管机构批准，其安全性和有效性尚未确立[6] - 美国FDA正在审评Aficamten的新药申请，处方药用户费用法案目标行动日期为2025年12月26日[6] - 欧洲药品管理局正在审评Aficamten的上市授权申请，中国国家药品监督管理局药品审评中心正在对Aficamten的新药申请进行优先审评[6] 公司业务与研发管线 - Cytokinetics是一家专业心血管生物制药公司，基于超过25年在肌肉生物学领域的开创性科学创新，致力于为心脏肌肉功能障碍患者开发潜在新药[7] - 公司除推进Aficamten的潜在监管批准和商业化准备外，还正在开发用于射血分数严重降低的心力衰竭患者的心肌肌球蛋白激活剂Omecamtiv Mecarbil、作用机制不同于Aficamten的心肌肌球蛋白抑制剂Ulamacaten，以及用于特定类型肌营养不良症的快骨骼肌肌钙蛋白激活剂CK-089[7]